For instance, Cetuximab, a EGFR-targeting inhibitor, was used in a large phase III clinical trial in Europe, and the experimental data suggested that, FOLFOX4+Cetuximab (n=791) could not extend the disease-free survival (DFS) of stage III CRC patients after surgical resection, which was true even for KRAS wild-type patients [33]. The gene discussed is KRAS; the disease is colorectal carcinoma.